PRODUCTS / PRODUCT PORTFOLIO

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, diseases and pain.

12 3 4

Product	Indication	Dosage form	Strength
	Depression	Tablets	10 and 20 mg
Amitriptyline	Major depressive disorders and anxiety	Film-coated tablets	10, 25, 50 and 75 mg
Aripiprazole	Schizophrenia, bipolar disorder	Tablets	5, 10, 15, 20 and 30 mg
Baclofen	Spasticity	Injection	10 mg/5 ml and 10 mg/20 ml
Baclofen	Spasticity	Tablets	25 mg
Buprenorphine	Opioid dependence		0,4/ 1/ 2/ 4/ 6 & 8 mg sublingual films
Clonazepam	Epilepsy	Oral drops, solution	2.5 mg/ml
Clonazepam	Epilepsy	Tablets	0.5 and 2 mg
Duloxetine *	Major depressive disorders, neuropathic pain, anxiety	Gastro resistant hard capsules	30, 60, 90 and 120 mg
Eslicarbazepine acetate	Epilepsy	Film-coated tablets	800 mg
Ethosuximide	Epilepsy, absence seizures	Soft capsules	250 mg
Ethosuximide	Epilepsy, absence seizures	Oral solution	250mg / 5ml
Fampridine	Multiple sclerosis	XR tablets	10 mg
Fingolimod	Multiple sclerosis	Capsules	0.5 mg
Fluoxetine	Depression	Tablets	10 and 20 mg
Flupentixol decanoate	Schizophrenia	Injection	10mg/ 0,5 ml; 20mg/ ml; 40mg/ ml; 200mg / 10 ml
Lacosamide	Epilepsy	Oral solution	10 mg/ml syrup
Lamotrigine	Lamotrigine	XR tablets	25/ 50/ 100/ 200 & 300 mg
Levetiracetam	Epilepsy	Film-coated tablets	250, 500, 750 and 1000 mg
Levetiracetam	Epilepsy	Granules for oral solution	250, 500, 750, 1000 and 1500 mg

FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.